Select Page

Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 Million Pharmaceutical Market Opportunity

Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 Million Pharmaceutical Market Opportunity
609683.png

The company published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.

DALLAS, April 17, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE

Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.

KALY owns and operates a patented cannabis extraction process. Following four years of research and development, the company recently executed a strategy to bring the resulting intellectual property (IP) into a public company as part of a plan to capitalize its next stage of development.

KALY is that public company platform.  In conjunction with that plan, the company has recently disclosed four of its leading research and development initiatives targeting four specific health issues:

  • Chronic Obstructive Pulmonary Disease (COPD) – The market for COPD treatment is anticipated to reach $14 billion by 2025;
  •  Type 2 Diabetes – The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
    Cancer Pain Management – The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
  •  Epilepsy – The market for epilepsy treatment is anticipated to reach $9 billion by 2022.The presentation below and incorporated into the company’s website offers further detail on the company’s progress to date and plans moving forward to commercialize cannabis therapies.Chronic Obstructive Pulmonary Disease (COPD) – The market for COPD treatment is anticipated to reach $14 billion by 2025;
  •  Type 2 Diabetes – The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
    Cancer Pain Management – The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
  •  Epilepsy – The market for epilepsy treatment is anticipated to reach $9 billion by 2022.

Cannabis Research Methodology

To accelerate development, KALY is developing key partners with an emphasis on establishing joint ventures with existing biopharmaceutical companies.  The company has a $3.5 million development plan for its next stage of development and management is working diligently to fund that development plan through the capital structure of partner companies.

Leave a Reply

avatar

Join Our Newsletter

Get stock alerts, news & related alerts straight to your inbox!